Table 5.

Efficacy of microRNAs used in diagnosing hepatitis B virus-associated hepatocellular carcinoma with low alpha fetoprotein expression

AFP level in HBV-HCC patients	Comparison	miRNA	AUC	Sensitivity	Specificity	Ref.
< 15 ng/mL	HBV-DN	let-7b	0.645	0.848	0.500	[233]
< 15 ng/mL	HBV-DN	miR-122	0.629	0.712	0.577	[233]
< 15 ng/mL	HBV-DN	miR-122 + let-7b	0.646	0.848	0.500	[233]
≤ 20 ng/mL	CHB + HC	miR-26a	0.733	0.868	0.574	[30]
≤ 20 ng/mL	CHB + HC	miR-26a1	0.701	0.880	0.574	[30]
≤ 20 ng/mL	CHB + HC	miR-27a	0.832	0.838	0.723	[30]
≤ 20 ng/mL	CHB + HC	miR-27a1	0.771	0.800	0.723	[30]
≤ 20 ng/mL	CHB + HC	miR-125b	0.778	0.760	0.790	[30]
≤ 20 ng/mL	CHB + HC	miR-125b1	0.775	0.800	0.787	[30]
≤ 20 ng/mL	CHB + HC	miR-223	0.759	0.789	0.702	[30]
≤ 20 ng/mL	CHB + HC	miR-2231	0.715	0.720	0.723	[30]
< 20 ng/mL	CHB + HC	miR-15b + miR-130b	0.980	0.967	0.915	[9]
≤ 20 ng/mL	CHB + HC	miR-125b + miR-223 + miR-27a + and miR-26a	0.874	0.842	0.851	[30]
≤ 20 ng/mL	CHB + HC	miR-125b + miR-223 + miR-27a + miR-26a1	0.849	0.800	0.894	[30]
< 200 ng/mL	CHB	miR-125b	0.943	1.000	0.755	[23]
< 250 ng/mL	CHB	miR-126	0.765	0.610	0.690	[32]
< 250 ng/mL	HBV-LC	miR-126	0.643	0.610	0.580	[32]
< 400 ng/mL	HBV-LC	miR-205	0.815	1.000	0.560	[36]
20-400 ng/mL	CHB + HC	miR-15b + miR-130b	0.976	1.000	0.915	[9]
< 400 ng/mL	CHB + HBV-LC + HC	miR-122 + miR-192 + miR-21 + miR-223 + miR-26a + miR-27a + miR-801	0.879	0.777	0.845	[44]

¹Comparing early-stage hepatitis B virus-associated hepatocellular carcinoma patients to patients with other stages.

HBV-DN: Hepatitis B virus-related dysplastic nodule patient; CHB: Chronic hepatitis B patient; HC: Healthy control; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HBV-LC: Hepatitis B virus-related liver cirrhosis patient; AFP: Alpha fetoprotein; AUC: Area under the receiver operating characteristic curve; miRNAs: MicroRNAs.